Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
852 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06351527 | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies | recruiting | Phase 1 | 78 | InnoCare Pharma Inc.INDUSTRY | 3 | Jun 19, 2025 | clinicaltrials |
| NCT00769379 | Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy | completed | Phase 3 | 2,014 | National Cancer Institute (NCI)NIH | 4 | Jun 12, 2025 |
| clinicaltrials |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer(CheckMate 7DX) | completed | Phase 3 | 1,030 | Bristol-Myers SquibbINDUSTRY | 28 | Jun 12, 2025 | clinicaltrials |
| NCT01974440 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma(SELENE) | completed | Phase 3 | 403 | Janssen Research & Development, LLCINDUSTRY | 19 | May 25, 2025 | clinicaltrials |
| NCT03941860 | Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial | completed | Phase 3 | 1 | National Cancer Institute (NCI)NIH | 2 | May 23, 2025 | clinicaltrials |
| NCT04068103 | Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | active not recruiting | Phase 2 / Phase 3 | 635 | NRG OncologyOTHER | 3 | May 7, 2025 | clinicaltrials |
| NCT05067972 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors(C4431001) | terminated | Phase 1 | 30 | PfizerINDUSTRY | 2 | May 6, 2025 | clinicaltrials |
| NCT02492711 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer(SOPHIA) | completed | Phase 3 | 624 | MacroGenicsINDUSTRY | 18 | Mar 17, 2025 | clinicaltrials |
| NCT02828358 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 4 | Feb 27, 2025 | clinicaltrials |
| NCT03213691 | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Feb 5, 2025 | clinicaltrials |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | completed | Phase 2 | 274 | Bristol-Myers SquibbINDUSTRY | 17 | Feb 5, 2025 | clinicaltrials |
| NCT01833039 | An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | approved for marketing | — | — | Janssen Biotech, Inc.INDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT03649971 | A Study of Guselkumab in Participants With Familial Adenomatous Polyposis | completed | Phase 1 | 77 | Janssen Research & Development, LLCINDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT05144009 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)(LOTIS-9) | terminated | Phase 2 | 41 | ADC Therapeutics S.A.INDUSTRY | 4 | Jan 30, 2025 | clinicaltrials |
| NCT01573442 | Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment | completed | Phase 3 | 227 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jan 28, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT03511664 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer(VISION) | completed | Phase 3 | 861 | EndocyteINDUSTRY | 10 | Jan 13, 2025 | clinicaltrials |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL) | completed | Phase 3 | 521 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 8, 2025 | clinicaltrials |
| NCT03204916 | Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia | completed | — | 301 | Children's Oncology GroupNETWORK | 2 | Jan 6, 2025 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT02528643 | A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 165 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Dec 6, 2024 | clinicaltrials |
| NCT04340193 | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer(CheckMate 74W) | completed | Phase 3 | 26 | Bristol-Myers SquibbINDUSTRY | 19 | Nov 26, 2024 | clinicaltrials |
| NCT01871727 | A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma | completed | Phase 3 | 112 | Eisai Inc.INDUSTRY | 3 | Nov 13, 2024 | clinicaltrials |
| NCT06426628 | Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier(NIGHTINGALE) | recruiting | — | 2,400 | Veracyte, Inc.INDUSTRY | 2 | Nov 13, 2024 | clinicaltrials |
| NCT06448364 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination(LTbR) | terminated | Phase 1 | 4 | PfizerINDUSTRY | 2 | Nov 6, 2024 | clinicaltrials |
| NCT04101526 | Developing and Testing a Spanish-Language Intervention to Reduce Cancer-Related Sleep Disturbance | completed | N/A | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 2 | Oct 29, 2024 | clinicaltrials |
| NCT03721978 | REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | completed | Phase 3 | 203 | Inovio PharmaceuticalsINDUSTRY | 10 | Oct 17, 2024 | clinicaltrials |
| NCT04737187 | Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients(SUNLIGHT) | completed | Phase 3 | 492 | Taiho Oncology, Inc.INDUSTRY | 14 | Sep 24, 2024 | clinicaltrials |
| NCT03668119 | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)(CheckMate 848) | completed | Phase 2 | 212 | Bristol-Myers SquibbINDUSTRY | 17 | Aug 28, 2024 | clinicaltrials |
| NCT03206450 | Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors | completed | — | 224 | Children's Oncology GroupNETWORK | 3 | Aug 26, 2024 | clinicaltrials |
| NCT03278925 | Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis | unknown | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 2 | Aug 2, 2024 | clinicaltrials |
| NCT02135419 | Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions(ANCHOR) | completed | Phase 3 | 4,446 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 26, 2024 | clinicaltrials |
| NCT03602586 | Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2024 | clinicaltrials |
| NCT02847728 | Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice | completed | — | 1,189 | Bristol-Myers SquibbINDUSTRY | 14 | Jun 3, 2024 | clinicaltrials |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | terminated | Phase 3 | 48 | QED Therapeutics, a BridgeBio companyINDUSTRY | 15 | May 8, 2024 | clinicaltrials |
| NCT02247349 | BMS-986012 in Relapsed/Refractory SCLC | completed | Phase 1 / Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 5, 2024 | clinicaltrials |
| NCT02470091 | Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma | completed | Phase 2 | 56 | Children's Oncology GroupNETWORK | 3 | Jan 22, 2024 | clinicaltrials |
| NCT04887506 | TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | completed | Phase 3 | 107 | Tavanta TherapeuticsINDUSTRY | 8 | Jan 16, 2024 | clinicaltrials |
| NCT03138499 | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,(CheckMate 812) | terminated | Phase 3 | 23 | Bristol-Myers SquibbINDUSTRY | 3 | Jan 10, 2024 | clinicaltrials |
| NCT01872975 | Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery | active not recruiting | N/A | 1,636 | NSABP Foundation IncNETWORK | 7 | Dec 27, 2023 | clinicaltrials |
| NCT05820191 | B-amyloid as a Marker for GBM Bioimaging | unknown | Phase 2 | 3 | Universidad Central del CaribeOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT03414983 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread(CheckMate 9X8) | completed | Phase 2 / Phase 3 | 196 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 18, 2023 | clinicaltrials |
| NCT01946139 | Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV | completed | N/A | 276 | AIDS Malignancy ConsortiumNETWORK | 2 | Nov 7, 2023 | clinicaltrials |
| NCT02484443 | Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 5 | Oct 26, 2023 | clinicaltrials |
| NCT04661176 | Evaluation of the Sentinel™ PCC4 Assay for Diagnosis, Prognosis and Monitoring of Prostate Cancer in Puerto Rico | unknown | — | 500 | miR Scientific LLCINDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT03689712 | ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients | completed | Phase 3 | 455 | Galera Therapeutics, Inc.INDUSTRY | 3 | Oct 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials